- Human application of the CSIRO hairpin RNAi IP - Proprietary gene therapy IP (DNA cassettes, transgenic delivery, etc.) 5 x Alnylam InterfeRx licenses 1 x HIV stem cell therapeutic at CoH 1 x HIV T-cell therapeutic at CoH - License to use CoH gene therapy IP - 4.2% of Tacere - License/Royalty deal over the TT-033 IP - Preclinical development agreement for Hepatitis B with Biomics - Reagents revenue from the application of expressed RNAi to the research process (Sigma Aldrich, Promega, etc.)
Single lines of the above could be worth $50m.
Finally, add in the possibility of some fundamental RNAi IP - like acknowledgement, in patent terms, that Benitec was "first in animal cell" to conceive of the therapeutic application of RNAi. This is being battled with the USPTO - but it is already acknowledged throughout the British commonwealth ...
I am not really fussed if no one offers us $1 per share - as long as we have the ability to justify such a price in terms of development/license/royalty income streams.
BLT Price at posting:
4.3¢ Sentiment: Buy Disclosure: Held